Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations

[1]  T. Friede,et al.  Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Thomassen,et al.  Clinical utility gene card for: Alport syndrome – update 2014 , 2014, European Journal of Human Genetics.

[3]  K. Voskarides,et al.  Frequency of COL4A3/COL4A4 Mutations amongst Families Segregating Glomerular Microscopic Hematuria and Evidence for Activation of the Unfolded Protein Response. Focal and Segmental Glomerulosclerosis Is a Frequent Development during Ageing , 2014, PloS one.

[4]  C. Deltas,et al.  Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  A. Adeyemo,et al.  Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis , 2014, Kidney international.

[6]  O. Gross,et al.  Challenges for academic investigator-initiated pediatric trials for rare diseases. , 2014, Clinical Therapeutics.

[7]  J. Savige,et al.  COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. , 2013, Journal of the American Society of Nephrology : JASN.

[8]  S. Korbet,et al.  The variable course of women with X-linked Alport Syndrome , 2013, Clinical kidney journal.

[9]  D. Rubel,et al.  Alport syndrome—insights from basic and clinical research , 2013, Nature Reviews Nephrology.

[10]  Jie Ding,et al.  Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. , 2013, Journal of the American Society of Nephrology : JASN.

[11]  Tim Friede,et al.  Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients , 2012, ISRN pediatrics.

[12]  R. Torra,et al.  Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. , 2012, Kidney international.

[13]  Jie Ding,et al.  Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative , 2012, Pediatric Nephrology.

[14]  T. Friede,et al.  Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. , 2012, Kidney international.

[15]  M. Rheault.  Women and Alport syndrome , 2011, Pediatric Nephrology.

[16]  M. Bekheirnia,et al.  Genotype-phenotype correlation in X-linked Alport syndrome. , 2010, Journal of the American Society of Nephrology : JASN.

[17]  J. Fries,et al.  Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  C. Kashtan.  Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  B. Beirowski,et al.  Chronic renal failure and shortened lifespan in COL4A3+/- mice: an animal model for thin basement membrane nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[20]  M. Gregory.  The clinical features of thin basement membrane nephropathy. , 2005, Seminars in nephrology.

[21]  Douglas G Altman,et al.  The logrank test , 2004, BMJ : British Medical Journal.

[22]  H. Smeets,et al.  X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. , 2003, Journal of the American Society of Nephrology : JASN.

[23]  K. Tryggvason,et al.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.

[24]  O. Gross,et al.  Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  O. Gross,et al.  Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  G. Mollet,et al.  Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. , 2001, Journal of the American Society of Nephrology : JASN.

[27]  H. Smeets,et al.  X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. , 2000, Journal of the American Society of Nephrology : JASN.

[28]  J. Savige,et al.  Thin basement membrane nephropathy. , 2003, Kidney international.

[29]  P. Frederik,et al.  Thin-basement-membrane nephropathy in adults with persistent hematuria. , 1989, The New England journal of medicine.